Session » B cell Biology and Targets in Rheumatolid Arthritis and other Autoimmune Disease Poster

Date: Monday, November 9, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1110

A Proliferative Inducing Ligand (APRIL) Promotes IL-10 Production of Human B Cells

9:00AM-11:00AM: Abstract Number: 1093

Activation of Syk-Btk Signal in Peripheral Blood B Cells in Patients with Rheumatoid Arthritis: A Potential Target for Abatacept Therapy

9:00AM-11:00AM: Abstract Number: 1120

Analysis of SLE Plasmablasts By High Throughput Pairing of the Immunoglobulin Heavy and Light Chain (VH-VL)

9:00AM-11:00AM: Abstract Number: 1122

B Cell Phenotypic Changes in Anti-Nuclear Antibody Positive Individuals Prior to the Onset of Systemic Autoimmune Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1113

B Cell Signature Profiling in Systemic Lupus Erythematosus Patients on Belimumab

9:00AM-11:00AM: Abstract Number: 1115

B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers

9:00AM-11:00AM: Abstract Number: 1096

B Cells Are Prime Producers of Tumor Necrosis Factor Alpha in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1121

Breach of B Cell Anergy in New Zealand Black Congenic Mice

9:00AM-11:00AM: Abstract Number: 1124

Bruton’s Tyrosine Kinase Levels Are Increased in B Cells from Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1102

CD19+CD24-CD38hi B-Cell Subset: A Potential Biomarker for IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1100

Citrullinated Antigen-Specific B Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis: Identification and Phenotypic Characterization

9:00AM-11:00AM: Abstract Number: 1109

Co-Crystal Structure of TACI and APRIL-BAFF-BAFF Heteromer Suggests That Charged Residues in APRIL and BAFF Dictate Their Receptor Binding Affinities

9:00AM-11:00AM: Abstract Number: 1116

Decreased Expression of Negative Regulators of Toll-like Receptor Signaling and Increased TLR7 Responsiveness in Expanded IgD- CD27- B Cells from Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1106

Efficacy of Abbv-105, a Selective and Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Multiple Models of Inflammation

9:00AM-11:00AM: Abstract Number: 1108

Epratuzumab, a Monoclonal Antibody Targeting CD22 on B Cells, Stimulates the Phosphorylation of Upstream Inhibitory Signals of the B Cell Receptor

9:00AM-11:00AM: Abstract Number: 1119

High Resolution Motif Mapping of in Situ Anti-Native-Vimentin Antibodies in Lupus Tubulointerstitial Nephritis

9:00AM-11:00AM: Abstract Number: 1095

Identification of Carbamylated Alpha-1-Anti-Trypsin (A1AT) As an Antigenic Target of Anti-Carp Antibodies in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1094

Increased IgA Plasmablasts Are Associated with Rheumatoid Arthritis-Related Autoantibodies in the Absence of Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1107

Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22

9:00AM-11:00AM: Abstract Number: 1098

Interleukin-1 Reciprocally Regulates Interferon-Gamma Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) and Interleukin-6 in Human Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 1101

Matrix Metalloproteinase-10 (Stromelysin 2) Is a Target of Robust Autoimmune T and B Cell Responses in Antibiotic-Refractory Lyme Arthritis, but Not in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1104

Mouse B Cells Require Glucose and Free Fatty Acids As Carbon Sources for Cytokine and Chemokine Secretion

9:00AM-11:00AM: Abstract Number: 1125

Next-Generation Sequencing Demonstrates Dynamic Recirculation of B Cell Clones in Ectopic Lymphoid Structures of Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1112

Obinutuzumab Outperforms Rituximab at Inducing B-Cell Cytotoxicity in Vitro through Fc-Mediated Effector Mechanisms in Rheumatoid Arthritis and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1103

Phosphatidylserine Outer Layer Translocation Is Implicated in IL-10 Secretion By Human Regulatory B Cells

9:00AM-11:00AM: Abstract Number: 1097

Pre-Clinical Development of a Novel, Potent and Selective BTK Inhibitor for Autoimmune Disease and Inflammation Including Arthritis

9:00AM-11:00AM: Abstract Number: 1114

Profiling Circulating Plasmablasts from Anti-Ro Positive Mothers of Children with Congenital Heart Block to Identify Antigenic Targets Conferring Pathogenicity

9:00AM-11:00AM: Abstract Number: 1126

Pyrrolopyrimidine Derivatives That Inhibit BAFF Binding to Its Receptor, BR3, Decrease IgG Production By B Cells in Vitro and in Vivo Model of Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 1123

Regulatory B Cells Regulate Skin and Lung Fibrosis and Immunological Abnormalities in a Topoisomerase I and Complete Freund’s Adjuvant-Induced Scleroderma Model Via an Antigen-Specific Manner

9:00AM-11:00AM: Abstract Number: 1111

Relapse of Lupus after B-Cell Depletion Therapy Is Associated with Loss of Apoptotic Cell Clearance and Elevated Type I Interferon Responses in Lupus Prone BXD2

9:00AM-11:00AM: Abstract Number: 1118

Role of the Chemokine Receptor CXCR3 in the Function of Regulatory B Cells in Patients with SLE

9:00AM-11:00AM: Abstract Number: 1099

Single Cell RNA-Seq Analysis of Citrullinated Alpha-Enolase Peptide-Specific B Cells in RA

9:00AM-11:00AM: Abstract Number: 1117

The B Cell Survival Cytokine BAFF Promotes Systemic Lupus Erythematosus Via Activation of TACI, Not BAFF Receptor

9:00AM-11:00AM: Abstract Number: 1105

The IgG/IgG4 mRNA Ratio By Quantitative PCR Accurately Diagnoses IgG4-Related Disease and Predicts Treatment Response

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].